Short Interest in Bavarian Nordic A/S (OTCMKTS:BVNRY) Declines By 66.7%

Bavarian Nordic A/S (OTCMKTS:BVNRY) was the recipient of a large decrease in short interest in the month of November. As of November 15th, there was short interest totalling 400 shares, a decrease of 66.7% from the October 31st total of 1,200 shares. Based on an average trading volume of 81,400 shares, the short-interest ratio is currently 0.0 days.

Bavarian Nordic A/S Price Performance

OTCMKTS:BVNRY traded up $0.15 during mid-day trading on Thursday, hitting $8.99. The company’s stock had a trading volume of 8,831 shares, compared to its average volume of 33,372. The business’s fifty day moving average is $10.32 and its two-hundred day moving average is $9.94. The stock has a market cap of $2.13 billion, a price-to-earnings ratio of 13.03 and a beta of 1.71. Bavarian Nordic A/S has a 1 year low of $6.86 and a 1 year high of $14.60.

About Bavarian Nordic A/S

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.